Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2017

  • ID: 4426933
  • Report
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Hemispherx Biopharma Inc
  • Oncovir Inc
  • MORE
Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2017

Summary

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System and Other Diseases which include indications Breast Cancer, Asthma, Melanoma, Renal Cell Carcinoma, Acute Inflammation, Autoimmune Disorders, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Cutaneous T-Cell Lymphoma, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Solid Tumor, Ulcerative Colitis, West Nile Virus Infections and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
  • The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Hemispherx Biopharma Inc
  • Oncovir Inc
  • MORE
Introduction

Toll Like Receptor 3 (CD283 or TLR3) - Overview

Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development

Bioncotech Therapeutics SL

Hemispherx Biopharma Inc

MultiCell Technologies Inc

Oncovir Inc

Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles

Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BO-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CU-CPT4a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCT-465 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly-ICLC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PrEP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRV-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products

Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products

Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones

Featured News & Press Releases

Aug 14, 2017: Hemispherx Human Safety Study of Intranasal Ampligen with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated

Aug 08, 2017: Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Jul 10, 2017: Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer

May 31, 2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities

May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology

May 15, 2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017

Mar 06, 2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017

Feb 09, 2017: hVIVO announces data from two Phase IIa clinical studies to further profile PrEP Biopharm’s PrEP-001 as a potential prophylactic against the common cold

Jan 26, 2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe

Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME

Oct 19, 2016: Hemispherx Biopharma Announces Completion of Ampligen Manufacturing Technology Transfer Milestone

Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA

Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Bioncotech Therapeutics SL, H2 2017

Pipeline by Hemispherx Biopharma Inc, H2 2017

Pipeline by MultiCell Technologies Inc, H2 2017

Pipeline by Oncovir Inc, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bioncotech Therapeutics SL
  • Hemispherx Biopharma Inc
  • MultiCell Technologies Inc
  • Oncovir Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll